
Sona Provides Corporate Update – May 2022
Sona Nanotech announces the termination of its licensing agreement with Arlington Scientific for the Company’s COVID-19 rapid saliva test. The Company will continue to focus its efforts on the development of its concussion and bovine tuberculosis rapid tests, and on the development of its proprietary gold nanorod technology, including manufacturing capabilities, and key research studies to further validate its biocompatibility. The Company is also pleased to announce the dismissal of the class action suit filed in the U.S.